Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emergent extends BioThrax and R&D agreement with US government

This article was originally published in Scrip

Executive Summary

Emergent Biosolutionshas signed another deal with the US Department of Health and Human Services (HHS) to supply it with a further 14.5 million doses of BioThrax, an adsorbed anthrax vaccine, for the country's strategic national stockpile (SNS). Emergent could earn $364-404 million from the contract, with the higher amount dependant on the company delivering a product with a four-year expiry date.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC023614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel